Jonathan Friedberg: End Point Surrogacy in First-Line CLL

Jonathan Friedberg, Director of Wilmot Cancer Institute, posted the following on X:

“End Point Surrogacy in First-Line CLL: Given the clear PFS benefit in patients who achieve undetectable MRD after therapy, novel strategies incorporating MRD as an endpoint are ready for evaluation as a precision approach to CLL therapy. JCO ASCO”

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia

Authors: Florian Simon, MD, Rudy Ligtvoet, PhD, Sandra Robrecht, PhD, Paula Cramer, MD, Nadine Kutsch, MD, Moritz Fürstenau, MD, Valentin Goede, MD, Julia von Tresckow, MD, Petra Langerbeins, MD, Anna-Maria Fink, MD, Henriette Huber, MD, Eugen Tausch, MD, Christof Schneider, MD, Clemens M. Wendtner, MD, Matthias Ritgen, MD, Martin Dreyling, MD, Lothar Müller, MD, Lutz Jacobasch, MD, Werner J. Heinz, MD, Ursula Vehling-Kaiser, MD, Liliya Sivcheva, MD, Sebastian Böttcher, MD, Peter Dreger, MD, Thomas Illmer, MD, Michael Gregor, MD, Philipp B. Staber, MD, Stephan Stilgenbauer, MD, Carsten U. Niemann, MD, Arnon P. Kater, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Michael Hallek, MD, Othman Al-Sawaf, MD.